Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne
Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announced the publication of positive safety data from a long-term extension study evaluating Clascoterone cream 1% for acne in the online issue of Journal of the American Academy of Dermatology (JAAD).